AMPHOTERICIN B liposomal complex, 50mg, powder, vial
STD
DINJAMBL5V-
Valid Article
Account code:
60000
HS Code:
300490
Last Updated on:
02/09/2024, 22:02:04
Former
Code(s):
DINJAMPH5V-
6.3 - Antifungal medicines
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
6.5.2 - Antileishmaniasis medicines
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
J02AA01
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
AMPHOTERICIN B liposomal
Therapeutic Action
Antifungal medicine
Indications
Cryptococcal meningitis, when conventional amphotericin B is contra-indicated.
Cutaneomucous or visceral leishmaniasis
Severe histoplasmosis
Some restricted information has been hidden. Sign in
to see this information
Instructions for use
- Reconstitute the powder vial with 12 ml of water for injection to obtain a concentrated solution at 4 mg/ml amphotericin B.
- Using a syringe, withdraw the required dose of concentrated solution.
- Attach the filter provided with the vial to the syringe.
- Through the filter, inject the contents of the syringe, into the required volume of 5% glucose (50, 250 or 500 ml) to obtain a solution for IV infusion between 0.2 and 2 mg/ml amphotericin B.
The liposomal amphotericin B (AmBisome®) is better absorbed and has less risk of renal toxicity than the conventional amphotericin B (Fungizone®) for the treatment of cryptococcal meningitis.
Storage
- Powder: between 2ºC and 25°C. Do not refrigerate. Do not freeze. Protect from sunlight
- Solutions (concentrated and for infusion): keep refrigerated between 2°C and 8°C for 24hrs maximum. Do not freeze.